Sanofi-Aventis spins off Novexel
Sanofi-Aventis has spun off a new anti-infectives company it will call Novexel, which has received €40mm ($53mm) in venture funding. The investors, which hold a 66% interest in the company, were led by Atlas Venture and included Sofinnova Partners, 3i, and Novo AS. Sanofi-Aventis retains a 22% stake.
- Private Placement
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com